The emerging triple-negative breast cancer (TNBC) treatments target mitochondrial fission to combat paclitaxel (PTX) resistance.
Inositol's inhibition of this process makes it a potential therapy.
Multiparametric MRI provides an early and effective assessment of these innovations.
